ADAM10 and Alzheimer disease: Although systemic DAPG treatment of an AD animal model failed to prevent Aβ accumulation and memory decline, possibly because of the BBB impermeability predicted by computational approach, the present study suggests that DAPG is a novel AD drug candidate that reduces Aβ secretion through novel mechanisms such as regulation of ADAM10 and intracellular trafficking (Table 2 and Table 3, and Figure 11).